Literature DB >> 36112257

Some key considerations regarding the design and evaluation of high-throughput sequencing-based biallelic chimerism assays.

Matthijs Vynck1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 36112257     DOI： 10.1007/s12185-022-03452-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.319


× No keyword cloud information.
  3 in total

1.  Chimerism monitoring using biallelic single nucleotide or insertion/deletion polymorphisms: How many markers to screen?

Authors:  Matthijs Vynck; Friedel Nollet; Lode Sibbens; Helena Devos
Journal:  Clin Chim Acta       Date:  2022-06-03       Impact factor: 3.786

2.  Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.

Authors:  Lijie Han; Yilu Li; Jiaying Wu; Jie Peng; Xiaolin Han; Hongmian Zhao; Chen He; Yuanyuan Li; Weimin Wang; Mengmeng Zhang; Yafei Li; Hui Sun; Haixia Cao; Li'na Sang; Zhongxing Jiang; Jifeng Yu
Journal:  Int J Hematol       Date:  2022-08-28       Impact factor: 2.319

3.  A SNP panel for early detection of artificial chimerism in HSCT patients using TaqMan technology.

Authors:  Tikumphorn Sathirapatya; Wikanda Worrapitirungsi; Poonyapat Sukawutthiya; Kawin Rasmeepaisarn; Kornkiat Vongpaisarnsin
Journal:  Int J Legal Med       Date:  2020-04-05       Impact factor: 2.686
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.